Finally, “Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China” published in 2022, which recommends the use of finerenone to treat T2DM-CKD, to reduce urinary protein, delay the continuous decline of renal function, and lower the risk of end-stage renal disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization due to heart failure, with spironolactone and eplerenone being considered at discretion. This evidence concerns the gene NR3C2 and chronic kidney disease.